BCL-2 expression is prognostic for improved survival in non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 4, Issue 4, 2009, Pages 486-491

  Renouf, Daniel J ^a   Wood Baker, Richard ^a   Ionescu, Diana N ^a   Leung, Samuel ^a   Masoudi, Hamid ^a   Gilks, Cyril B ^a   Laskin, Janessa ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Bcl 2; EGFR; Immunohistochemistry; Non small cell lung cancer; Prognostic markers

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CHROMOGRANIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN BCL 2; PROTEIN P53; PROTEIN P63; SYNAPTOPHYSIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY; CHEMISTRY; LUNG TUMOR; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; TISSUE ARRAY ANALYSIS;

EID: 67649396222     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318199e03a     Document Type: Article

References (31)

1. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-1717. (Pubitemid 27260107)
2. Flehinger BJ, Kimmel M, Melamed MR. The effect of surgical treatment on survival from early lung cancer. Implications for screening. Chest 1992;101:1013-1018.
3. Lipford EH III, Eggleston JC, Lillemoe KD, et al. Prognostic factors in surgically resected limited-stage, nonsmall cell carcinoma of the lung. Am J Surg Pathol 1984;8:357-365.
4. Gail MH, Eagan RT, Feld R, et al. Prognostic factors in patients with resected stage I non-small cell lung cancer. A report from the Lung Cancer Study Group. Cancer 1984;54:1802-1813. (Pubitemid 14020608)
5. Macchiarini P, Fontanini G, Hardin MJ, et al. Blood vessel invasion by tumor cells predicts recurrence in completely resected T1 N0 M0 non-small-cell lung cancer. J Thorac Cardiovasc Surg 1993;106:80-89. (Pubitemid 23216049)
6. Takise A, Kodama T, Shimosato Y, et al. Histopathologic prognostic factors in adenocarcinomas of the peripheral lung less than 2 cm in diameter. Cancer 1988;61:2083-2088. (Pubitemid 18123494)
7. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980;65:25-32. (Pubitemid 10071592)
8. Zhu C-Q, Shih W, Ling C-H, Tsao M-S. Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol 2006;59:790-800. (Pubitemid 44211740)
9. Meert AP, Martin B, Delmotte P, et al. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J 2002;20:975-981. (Pubitemid 35175137)
10. Niemiec J, Kolodziejski L, Dyczek S. EGFR LI and Ki-67 LI are independent prognostic parameters influencing survivals of surgically treated squamous cell lung cancer patients. Neoplasma 2005;52:231-237. (Pubitemid 40776435)
11. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003;21:3798-3807. (Pubitemid 46606235)
12. Nakamura H, Kawasaki N, Taguchi M, et al. Survival impact of epidermal growth factor receptor overexpression in patients with nonsmall cell lung cancer: a meta-analysis. Thorax 2006;61:140-145. (Pubitemid 43235431)
13. Nakamura H, Kawasaki N, Taguchi M, et al. Association of HER-2overexpression with prognosis in nonsmall cell lung carcinoma: a metaanalysis. Cancer 2005;103:1865-1873. (Pubitemid 40563259)
14. Au N H, Cheang M, Huntsman DG, et al. Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. J Pathol 2004;204:101-109. (Pubitemid 39214487)
15. Pelosi G, Del Curto B, Dell'Orto P, et al. Lack of prognostic implications of Her-2/neu abnormalities in 345 stage 1 non-small cell carcinomas (NSCLC) and 2007 stage I - III neuroendocrine tumors (NET) of the lung. Int J Cancer 2005;113:101-108. (Pubitemid 39507316)
16. Yang WI, Zukerberg LR, Motokura T. Cyclin D1 (Bcl-1, PRAD1) protein expression in low-grade B-cell lymphomas and reactive hyperplasia. Am J Pathol 1994;145:86-96. (Pubitemid 24217487)
17. Caputi M, Groeger AM, EspositoV. Prognostic role of cyclin D1 in lung cancer. Am J Respir Cell Mol Biol 1999;20:746-750.
18. Steels E, Paesmans M, Berghmans T, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 2001;18:705-719. (Pubitemid 33040631)
19. Mitsudomi T, Hamajima N, Ogawa M, et al. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a metaanalysis. Clin Cancer Res 2000;6:4055-4063. (Pubitemid 30807100)
20. Tammemagi MC, McLaughlin JR, Bull SB. Meta-analyses of p63 tumor suppressor gene alterations and clinicopathological features in resected lung cancers. Cancer Epidemiol Biomarkers Prev 1999;8:625-634.
21. Massion PP, Taflan PM, Rahman SM, et al. Significance of p63 and overexpression in lung cancer development and prognosis. Cancer Res 2003;63:7113-7121. (Pubitemid 37413448)
22. Martin B, Peasmans M, Berhmans T, et al. Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2003;89:55-64. (Pubitemid 36897935)
23. Martins SJ, Ho VL, Capelozzi TY, et al. Thyroid transcription factor-1 and matrix metalloproteinase-9 with lung adenocarcinoma. J Clin Oncol 2005 ASCO Annual Meeting Proceedings supplement 2005;7207.
24. Takamochi K, Nagai K, Suzuki K. Clinical predictors of N2 disease in non-small cell lung cancer. Chest 2000;117:1577-1582. (Pubitemid 30413347)
25. Pelosi G, Pasini F, Sonzogni A, et al. Prognostic implications of neuroendocrine differentiation and hormone production in patients with stage I nonsmall cell lung carcinoma. Cancer 2003;97:2487-2497. (Pubitemid 36542488)
26. Ionescu D, Treaba D, Gilks CB, et al. Nonsmall cell lung carcinoma with neuroendocrine differentiation-an entity of no clinical or prognostic significance. Am J Surg Pathol 2007;31:26-32. (Pubitemid 46036899)
27. Wang S, Saboorian H, Frenkel E, et al. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridization assays. J Clin Pathol 2000;53:374-381. (Pubitemid 30256906)
28. Ruckdeschel J, Linnoila RI, Mullshine JL, et al. The impact of neuroendocrine and epithelial differentiation on recurrence and survival in patients with lung cancer Abstract. Proc Am Soc Clin Oncol 1991;10:248.
29. Martinez-Arribas F, Alvarez T, Del Val G, et al. Bcl-2 expression in breast cancer: a comparative study at the mRNA and protein level. Anticancer Res 2007;27:219-222. (Pubitemid 46363335)
30. Manion MK, Fry J, Schwartz PS, Hockenbery DM. Small-molecule inhibitors of Bcl-2. Curr Opin Invest Drugs 2006;7:1077-1084. (Pubitemid 44941752)
31. Tsao MS, Aviel-Ronen S, Ding K. P53 protein over-expression but not p53 gene mutation is a poor prognostic marker and a predictive marker for survival benefit from adjuvant chemotherapy in non-small cell lung cancer (NSCLC) in the JBR. 10 Trial. J Clin Oncol 2007; 18S (20 Suppl), 2007:7577.